Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al.
The regulation of biosimilars
Why do charities need to keep funding research into leukemia and blood cancer in general?
Developments in Hodgkin lymphoma, CLL, multiple myeloma and follicular lymphoma
Relapse in DLBCL - addressing the unmet need with brentuximab vedotin